D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 80 Citations 35,840 426 World Ranking 9734 National Ranking 317

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Surgery
  • Cancer

His primary areas of study are Internal medicine, Surgery, Gastroenterology, Crohn's disease and Ulcerative colitis. As part of his studies on Internal medicine, Geert R. D'Haens frequently links adjacent subjects like Placebo. His Surgery research is multidisciplinary, relying on both Adalimumab, Certolizumab pegol, Clinical trial and Dosing.

His Gastroenterology study combines topics from a wide range of disciplines, such as Crohn's Disease Activity Index, Intestinal mucosa, Rheumatoid arthritis and C-reactive protein. His Crohn's disease study integrates concerns from other disciplines, such as Colonoscopy, Faecal calprotectin and Severity of illness. His Ulcerative colitis study combines topics in areas such as Gastrointestinal agent, Interquartile range and Colitis.

His most cited work include:

  • Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. (2984 citations)
  • Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial (971 citations)
  • Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis (782 citations)

What are the main themes of his work throughout his whole career to date?

His main research concerns Internal medicine, Crohn's disease, Gastroenterology, Ulcerative colitis and Inflammatory bowel disease. As a member of one scientific family, Geert R. D'Haens mostly works in the field of Internal medicine, focusing on Placebo and, on occasion, Maintenance therapy. His study focuses on the intersection of Crohn's disease and fields such as Surgery with connections in the field of Azathioprine.

The various areas that Geert R. D'Haens examines in his Gastroenterology study include Moderate to severe, Adverse effect, Vedolizumab, Calprotectin and C-reactive protein. His work deals with themes such as Prospective cohort study, Tofacitinib, Colitis and Quality of life, which intersect with Ulcerative colitis. His studies link Intensive care medicine with Inflammatory bowel disease.

He most often published in these fields:

  • Internal medicine (68.95%)
  • Crohn's disease (47.37%)
  • Gastroenterology (46.32%)

What were the highlights of his more recent work (between 2019-2021)?

  • Internal medicine (68.95%)
  • Crohn's disease (47.37%)
  • Gastroenterology (46.32%)

In recent papers he was focusing on the following fields of study:

Geert R. D'Haens mainly investigates Internal medicine, Crohn's disease, Gastroenterology, Ulcerative colitis and Inflammatory bowel disease. Geert R. D'Haens performs multidisciplinary study in Internal medicine and In patient in his work. His studies in Crohn's disease integrate themes in fields like Post-hoc analysis, Clinical trial, Surgery and Ustekinumab.

His research on Gastroenterology also deals with topics like

  • Placebo which connect with Randomized controlled trial and Maintenance therapy,
  • Receiver operating characteristic which is related to area like Area under the curve. His Ulcerative colitis research is multidisciplinary, incorporating perspectives in Adverse effect, Prospective cohort study, Tofacitinib and Endoscopy. His Inflammatory bowel disease research incorporates elements of Colorectal cancer, Colitis, Ultrasound and Intensive care medicine.

Between 2019 and 2021, his most popular works were:

  • Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting. (94 citations)
  • Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis. (34 citations)
  • Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. (34 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Cancer
  • Disease

His primary scientific interests are in Internal medicine, Gastroenterology, Crohn's disease, Ulcerative colitis and Inflammatory bowel disease. He works mostly in the field of Internal medicine, limiting it down to topics relating to Placebo and, in certain cases, Endoscopy. Geert R. D'Haens interconnects C-reactive protein, Phases of clinical research, Adverse effect, Maintenance therapy and Receiver operating characteristic in the investigation of issues within Gastroenterology.

Within one scientific family, Geert R. D'Haens focuses on topics pertaining to Hazard ratio under Crohn's disease, and may sometimes address concerns connected to Terminal Ileitis, Retrospective cohort study, Surgery, Proportional hazards model and Lower risk. His Ulcerative colitis research includes themes of Interleukin 23, Cancer, Dysplasia and Adenoma. His biological study spans a wide range of topics, including Interquartile range, Therapeutic drug monitoring, Drug, Intensive care medicine and Guselkumab.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

Eric Van Cutsem;Claus Henning Köhne;Erika Hitre;Jerzy Zaluski.
The New England Journal of Medicine (2009)

4212 Citations

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

Geert D'Haens;Filip Baert;Gert van Assche;Philip Caenepeel.
The Lancet (2008)

1258 Citations

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.

William J. Sandborn;Paul Rutgeerts;Robert Enns;Stephen B. Hanauer.
Annals of Internal Medicine (2007)

1133 Citations

Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

William J. Sandborn;Gert van Assche;Walter Reinisch;Jean–Frederic Colombel.
Gastroenterology (2012)

1084 Citations

Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease.

Filip Baert;Liesbeth Moortgat;Gert Van Assche;Philip Caenepeel.
Gastroenterology (2010)

850 Citations

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations

Gert Van Assche;Axel Dignass;Walter Reinisch;C. Janneke van der Woude.
Journal of Crohns & Colitis (2010)

837 Citations

Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease

Geert D'Haens;Marc Ferrante;Severine Vermeire;Filip Baert.
Inflammatory Bowel Diseases (2012)

773 Citations

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease

Severine Vermeire;Maja Noman;Gert van Assche;Filip Baert.
Gut (2007)

760 Citations

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

William J. Sandborn;Chinyu Su;Bruce E. Sands;Geert R. D’Haens.
The New England Journal of Medicine (2017)

754 Citations

Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis

Noortje G. Rossen;Susana Fuentes;Mirjam J. van der Spek;Jan G. Tijssen.
Gastroenterology (2015)

706 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Geert R. D'Haens

Laurent Peyrin-Biroulet

Laurent Peyrin-Biroulet

University of Lorraine

Publications: 320

William J. Sandborn

William J. Sandborn

University of California, San Diego

Publications: 304

Silvio Danese

Silvio Danese

Humanitas University

Publications: 228

Jean-Frederic Colombel

Jean-Frederic Colombel

Icahn School of Medicine at Mount Sinai

Publications: 214

Brian G. Feagan

Brian G. Feagan

University of Western Ontario

Publications: 200

Severine Vermeire

Severine Vermeire

KU Leuven

Publications: 199

Javier P. Gisbert

Javier P. Gisbert

Autonomous University of Madrid

Publications: 132

Walter Reinisch

Walter Reinisch

Medical University of Vienna

Publications: 127

Paul Rutgeerts

Paul Rutgeerts

KU Leuven

Publications: 118

Remo Panaccione

Remo Panaccione

University of Calgary

Publications: 111

Gert Van Assche

Gert Van Assche

KU Leuven

Publications: 109

Gerhard Rogler

Gerhard Rogler

University of Zurich

Publications: 106

Peter L. Lakatos

Peter L. Lakatos

McGill University

Publications: 104

David T. Rubin

David T. Rubin

University of Chicago

Publications: 103

Stephen B. Hanauer

Stephen B. Hanauer

Northwestern University

Publications: 98

Simon Travis

Simon Travis

John Radcliffe Hospital

Publications: 95

Trending Scientists

Uwe Stilla

Uwe Stilla

Technical University of Munich

David N. Figlio

David N. Figlio

Northwestern University

William Kress Bodin

William Kress Bodin

IBM (United States)

Yongfeng Zhang

Yongfeng Zhang

Rutgers, The State University of New Jersey

Syed H. Masood

Syed H. Masood

Swinburne University of Technology

David L. Bryce

David L. Bryce

University of Ottawa

Bryan D. Neff

Bryan D. Neff

University of Western Ontario

Richard P. Tucker

Richard P. Tucker

University of California, Davis

Ehud Ahissar

Ehud Ahissar

Weizmann Institute of Science

Lindsey L. Cohen

Lindsey L. Cohen

Georgia State University

Piero Marchetti

Piero Marchetti

University of Pisa

John M. Lachin

John M. Lachin

George Washington University

Sanjiv J. Shah

Sanjiv J. Shah

Northwestern University

Valorie A. Crooks

Valorie A. Crooks

Simon Fraser University

Stephen P. Heyneman

Stephen P. Heyneman

Vanderbilt University

Something went wrong. Please try again later.